Yakınlık uzatma tahlili testi, atipik parkinson sendromunun yeni tanısal biyobelirteçlerini ortaya koymaktadır.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

ObjectiveThe high degree of clinical overlap between atypical parkinsonian syndromes (APS) and Parkinson's disease (PD) makes diagnosis challenging. We aimed to identify novel diagnostic protein biomarkers of APS using multiplex proximity extension assay (PEA) testing.MethodsCerebrospinal fluid (CSF) samples from two independent cohorts, each consisting of APS and PD cases, and controls, were analysed for neurofilament light chain (NF-L) and Olink Neurology and Inflammation PEA biomarker panels. Whole-cohort comparisons of biomarker concentrations were made between APS (n=114), PD (n=37) and control (n=34) groups using logistic regression analyses that included gender, age and disease duration as covariates.ResultsAPS versus controls analyses revealed 11 CSF markers with significantly different levels in cases and controls (pConclusionsPEA testing has identified potential novel diagnostic biomarkers of APS.

İlgili konular